363 related articles for article (PubMed ID: 22233440)
1. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies.
Huang W; Li H; Gao C; Bo J; Wang Q; Zhao Y; Jing Y; Wang S; Zhu H; Dou L; Wang L; Yu L
Transfusion; 2012 Jun; 52(6):1354-62. PubMed ID: 22233440
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and safety of unmanipulated haploidentical peripheral blood stem cell transplantation on hematologic diseases].
Huang WR; Li HH; Jin XS; Wang SH; Bo J; Zhao Y; Jing Y; Zhu HY; Dou LP; Jia BJ; Wang QS; Gao CJ; Yu L
Zhonghua Nei Ke Za Zhi; 2013 May; 52(5):390-4. PubMed ID: 23945304
[TBL] [Abstract][Full Text] [Related]
3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.
Yamasaki S; Ohno Y; Taniguchi S; Yoshida T; Hayashi S; Ogawa H; Shimazaki C; Takahashi S; Kasai M; Wake A; Nishimura M; Tokunaga K; Gondo H; Takaue Y; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Feb; 33(3):279-89. PubMed ID: 14647250
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
6. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
7. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
8. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
9. [Non-T-cell depleted HLA haploidentical peripheral blood stem cell transplantation for hematological malignancies: report of 36 cases].
Yuan HL; Li L; Qu JH; Wen BZ; Jiang M; Hao JP; Chen R; Guo XH; Halida Y; Wang SZ; Ding LL
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):82-6. PubMed ID: 19563016
[TBL] [Abstract][Full Text] [Related]
10. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
Xu LP; Liu KY; Liu DH; Chen H; Han W; Chen YH; Wang Y; Huang XJ
Bone Marrow Transplant; 2010 Jun; 45(6):985-92. PubMed ID: 19898505
[TBL] [Abstract][Full Text] [Related]
11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
12. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
[TBL] [Abstract][Full Text] [Related]
13. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.
Chen XH; Gao L; Zhang X; Gao L; Zhang C; Kong PY; Liu H; Peng XG; Sun AH; Qi DG; Gong Y; Wang QY
Blood Cells Mol Dis; 2009; 43(1):98-104. PubMed ID: 19356956
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
16. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
17. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center.
Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Sun YQ; Huang XJ
Cancer; 2013 Mar; 119(5):978-85. PubMed ID: 23097265
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell count in the graft predicts relapse in patients with hematologic malignancies undergoing an HLA-matched related allogeneic peripheral blood stem cell transplant.
Rajasekar R; Lakshmi KM; George B; Viswabandya A; Thirugnanam R; Abraham A; Chandy M; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2010 Jun; 16(6):854-60. PubMed ID: 20138229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
